Periti P
Department of Preclinical and Clinical Pharmacology, University of Florence, Firenze, Italy.
J Chemother. 1995 Jun;7(3):221-3. doi: 10.1179/joc.1995.7.3.221.
This brief review article synthesizes the principal literature regarding the clinical status of co-trimoxazole compared to monotherapy with one of the two diaminopyrimidines available commercially: trimethoprim or brodimoprim. Both these inhibitors of bacterial dihydrofolate reductase compare favorably to co-trimoxazole as antimicrobial chemotherapy. Brodimoprim is characterized by its advantageous pharmacokinetics in comparison to both co-trimoxazole and trimethoprim.
这篇简短的综述文章综合了关于复方新诺明与两种市售二氨基嘧啶之一（甲氧苄啶或溴莫普明）单药治疗相比的临床状况的主要文献。这两种细菌二氢叶酸还原酶抑制剂作为抗菌化疗药物，与复方新诺明相比具有优势。与复方新诺明和甲氧苄啶相比，溴莫普明具有有利的药代动力学特征。
